Dr. Hany Sleem NHTMRI, ENREC

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

Group 1.3 Relationships between RECs in multi-centre, international studies –problems and solutions.
The Fourth African Ministerial Conference on Science and Technology (AMCOST IV) By Amr Farouk, PhD The Ministry Of Scientific Research, Egypt
Fundamentals of IRB Review. Regulatory Role of the IRB Authority to approve, require modifications in (to secure approval), or disapprove all research.
Introduction to Treat the Pain. The problem of unrelieved pain Globally, 7.3 million people die of cancer or HIV each year in moderate or severe pain.
Clinical Trials Medical Interventions
THE ETHICAL CONDUCT OF RESEARCH Chapter 4. HISTORY OF ETHICAL PROTECTIONS The Nuremberg Code The Office for Human Research Protections (OHRP), United.
AfDB - EBRD Joint conference in procurement reform in North Africa and SEMED Countries Marrakech 22 and 23 April 2013 Jordan Delegation 22-23/4/2013.
Working Group 4: Urban Governance for Risk Reduction: Mainstreaming Adaptation into Urban Planning and Development Chair: Prof. Shabbir Cheema Rapporteurs:
Central Asia Regional Health Security Workshop Co-organized with the Command Surgeon, US Central Command and the George C. Marshall European Center for.
Idara C.E.. Three ethical principles guides research with human participants. principle of Autonomy 1. The principle of Autonomy requires investigators.
IRB and the Community Member How You Can Get Involved Mary Lou Smith Elda Railey Conference Call Series on IRBs and Ethical Issues in Research Co-sponsored.
Biosafety and Biosecurity Challenges in the Caribbean Region Valerie Wilson Caribbean Med Labs Foundation Anticipating Global Biosecurity Challenges Istanbul,
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Clinical Research in South Africa - Ethical and Regulatory Processes NATIONAL HEALTH RESEARCH ETHICS COUNCIL Professor A Dhai Deputy Chair National Health.
Presented by Professor: Salwa Elgharib General Secretary of Supreme Council of Egyptian Universities
Planned Emergency Research Exception from Informed Consent Requirements September 2007.
PORTFOLIO COMMITTEE PRESENTATION Ms. Joyce Mogale (Interim CEO) Prof. Perez (Chair ) Supporting a long and healthy life for all South Africans NHLS ANNUAL.
M.M. El-FoulyAmman-Jordan 4/2011 Approaches and Experiences Arabic Perspective Mohamed M. El-Fouly National Research Centre Cairo – Egypt IDEAS General.
ACCESS TO MEDICINES - POLICY AND ISSUES
Projection of Psychiatry services By the year 2000 Project Objectives Continue to offer psychiatric services within  The Primary Health Care Services.
Institutional Review Board (IRB) What is our Purpose and Role for Ethical Research.
Public Health Preventive Medicine and Epidemiology Prof. Ashry Gad Mohammed MB, ChB. MPH, Dr P.H Prof. of Epidemiology College of Medicine King Saud University.
SARPAM Southern African Regional Programme for Access to Medicines and Diagnostics Presentation to Botswana TRIPS and Access to Medicines workshop 26 March.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
$100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 Terms Clinical Trial Facts.
Evaluation of Ethics Review Procedures for Research in Egypt Hany Sleem 1 Henry Silverman 2 1 National Hepatology and Tropical Medicine Research Institute,
Idara C.E.. Three ethical principles guides research with human participants. principle of Autonomy 1. The principle of Autonomy requires investigators.
Understanding Clinical Trials – Part 2 Georgianne Arnold, MD Professor of Pediatrics University of Pittsburgh Medical Center Pittsburgh Children’s Hospital.
Emerging SACHRP Issues K. Lynn Cates, MD Assistant Chief Research & Development Officer Director, PRIDE Office of Research & Development Department of.
VA Central IRB K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development Department of Veterans Affairs September.
Bulgarian National Hepatitis Plan and Compassionate Use Regulations Dr. Stanimir Hasardzhiev Executive Director, ELPA Chairperson, Hepasist REPUBLIC OF.
Quality Metrics of Performance of Research Ethics Committees Cristina E. Torres, PhD FERCAP Coordinator.
Project: EaP countries cooperation for promoting quality assurance in higher education Maria Stratan European Institute for Political Studies of Moldova.
Chapter 22 REGULATORY AND ADVISORY AGENCIES. Introduction 2.
HCA 497 MART Experience Tradition /hca497mart.com FOR MORE CLASSES VISIT
Quality Assurance in Egypt and the European Standards and Guidelines
A capacity building programme for patient representatives
Back to Basics – Approval Criteria
Egyptian Nuclear and Radiological Regulatory Authority (ENRRA)
Criteria for Assessing MHPSS Proposals Submitted through the CAP, CERF and HRF Funding Mechanisms to the Protection Cluster.
Roadmap for Health in All Policies in Sudan
Nordic Cooperation on Ethical Review Procedures Nordforsk – nordic trial alliance MIKA SCHEININ
Patricia M. Alt, Ph.D. Dept. of Health Science Towson University
Community Participation in Research
RIA: Communication – building credibility
Community Pharmacy: Sharing Our Vision
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Clinical Trials Medical Interventions
AAEA Role in Improving EPR Coordination Interventions among Arab Countries Abdelmajid Mahjoub Arab Atomic Energy Agency
The EAC Quality Infrastructure and WTO TBT Agreement.
ABSTRACT Problem statement: The Lao PDR National Drug Policy (NDP) Program, implemented by the Ministry of Health supported by the Swedish International.
Jeffrey M. Cohen, Ph.D. CIP President HRP Associates, Inc.
Bozeman Health Clinical Research
Antimicrobial Resistance: Plans for Korea and Beyond
Clinical Trials.
Effective Quality Assurance in Healthcare, Kyrgyzstan
National Programme for limiting spread of HIV/AIDS in Latvia 2008–2012
Investigator Responsibilities: What should we expect from researchers?
Rieke van der Graaf PhD UMC Utrecht, Julius Center
Introduction to the training
Quality and Accreditation in Health care setting
AGREEMENT FOR TRANSPARENCY The Case of Mexico
REGIONAL NETWORK FOR CIVIL ORGANIZATIONS ON MIGRATION – RNCOM
Cindy Murray NP Princess Margaret Cancer Centre
National Cancer Center
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Proposed Regional Medium-term Civil Registration and Vital Statistics Plan First Conference of African Ministers Responsible for Civil Registration August.
Roadmap for Health in All Policies in Sudan
IAEA - Department of Nuclear Safety & Security
Presentation transcript:

Dr. Hany Sleem NHTMRI, ENREC PAVING THE WAY The Ethics Of Alternative Clinical Trial Designs from Egyptian point of view Dr. Hany Sleem NHTMRI, ENREC

Egypt Population: about 92 million GDP/Capita : about 4.000 $ Number of registered Clinical trial : 1892 1892 clinical trials were conducted in Egypt with the number of clinical trials nearly tripling in the last few years making Egypt second to South Africa in African . The biggest country regarding population and clinical trial number in the Arab World and lowest GDP/Capita. The clinical trial law (draft) Arabic languages, (2012 ,2017). 23Pages . 18 Articles.

IRBs in Egypt More than 56 Institutional Review Board (IRB) have been registered in OHRP . And 42 of them registered in the Egyptian Network of Research Ethics Committees (ENREC). Cairo , October 2017

ENREC 10 years of commitment ENREC was created in 2008 to raise the harmonization between Research Ethics Committees (RECs) in reviewing of research proposals and to augment sharing of information and intellectual resources, policies and review strategies.  ENREC is operating under the auspices of NGO (Egyptian Society for Healthcare Development, ESHD).  Through holding bi-annual meetings of its members (18 meetings) and conducting several workshops on the ethics of scientific research . Cairo , October 2017

National Research Ethics Committee Ministry of Health (MOH) National Research Ethics Committee, 24 members,10 permanent members and additional 14 members divided into two committees each committee meets every two weeks in the presence of 17 members. the first National Committee established in 2006.

Egyptian Clinical Trial Review Process Institutional Scientific Committee 30 Days Research Ethics Committee National Organization For Drug Control & Research (NODCAR) 60 Days Ministry of Health (MOH) National Research Ethics Committee

Possibility for Alternative Trial Designs in Egypt Unique study populations and Rare diseases Need for Individually tailored therapies Special isolated Environments Public health urgency & Emergency situations Restricted resources coupled with an important need 11/17/2018

Alternative clinical trial designs are not common practice in Egyptian clinical trials. Only one Adaptive trial for a new drug submitted for review to the Egyptian regulatory authority last year. Egypt as a developing country is prone to infectious outbreaks or natural disaster thus it will be candidate to alternative clinical trial. At that time IRBs and regulatory authority must be standby for ethical decisions based on enough scientific and ethical understanding of these new types of trial.

There are no special training or awareness workshop for Egyptian regulatory authority and IRBs especially community members on this topic. Therefore, a series of 45 min presentation followed by 1 hour of focus group discussions. These presentations are based on GFBR 2017 Background paper, European Medicines Agency (2007) and Food and Drug Administration (2010) guidelines.

Points Covered in The Presentation Operational concerns e.g. complexity of adaptive designs , difficult interpretation of results Recruitment and undue inducements or coercion Safety concerns for patients in certain adaptive designs e.g. dose-escalation studies Fair inclusion/exclusion of participants Safety monitoring Informed consent process 11/17/2018

Points Covered in The Presentation 2 Vulnerable populations with diminished capacity to consent. Ethical acceptability of a no-treatment control arm? Identifying who is the research participant. Role of gatekeepers in protecting group interests / Role of gatekeeper permissions. Risk/ benefits assessment. Protection of vulnerable participants. 11/17/2018

Discussions will focus on the ethical dilemmas of Alternative clinical trial designs and their suitability to the Egyptian culture and regulations and this programme will be supported by ENREC. We began with last ENREC meeting and will target the two components of the Egyptian regulatory authority. ENREC 18th meeting attended by 30 participants include 12 IRBs Chairman or their representative .

Questions Did you hear about Alternative Trial Designs before? (Majority No) Can we control Therapeutic misconception in the Alternative Trial Designs? (Majority Yes) Can we have a high-quality informed consent in the Alternative Trial Designs? (Majority Yes) Waiver of informed consent is it accepted? (Majority Yes) 11/17/2018

Questions Can we consider a group of the community as a research participant? (Majority Yes) Is it ethical to intentionally infect healthy volunteers with a pathogen as part of the trial design? (Majority No) Can a well-informed participant consent to any amount of risk if the social value of the study is high enough? (Majority No) If yes do you treat them as Phase I with a bigger compensation? (Majority No) 11/17/2018

Alternative clinical trial designs in Egypt IRBs members in Egypt still lack knowledge regarding the new designs of clinical trial , this will affect their judgment in the review process . Alternative clinical trial designs, offer certain practical and logistical advantages in Egypt that can help simplify trial organization and fieldwork in our low resource settings. Building capacity and promotion of the advantages and drawbacks of new clinical trial design is essential. Dear. Professor / Chairman of the Research Ethics Committee   Hope this email finds you well.  According to the central administration's efforts to enhance research environment in the Arab Republic of Egypt to improve the protection of participants in research and based on the Ministerial Decree (No. 595 of 2012) for the registration of research ethics committees in colleges and research institutes and teaching hospitals. The Center Department for Health Research and Development adopted the Self-Assessment tool for research Ethics Committee of the Middle East Research Ethics Initiative (MERETI) and under the umbrella of the Ministry of Health and Population. This will give the Egyptian RECs the chance to evaluate the quality of their work and give the committees an opportunity to know if there is any shortcoming in their work to try to reform or avoid it in order to ensure the highest degree of protection of participants in research and the Egyptian society. Therefore, we ask you to complete the self-assessment tool in support of our efforts and to improve the efficiency of the audit systems to ensure good work performance and to strengthen the compatibility between the various committees in the audit systems and mechanisms. Sincere thanks and appreciation, Thank You